Free tool
FAERS Monitor: Nulojix
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125288 or its brand name (Nulojix, Belatacept). Reports on generic versions are filed under their own applications.
Reports
4,739
Serious
3,595
76% of reports
Hospitalization
1,797
Death reported
750
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use463
- death232
- transplant rejection231
- kidney transplant rejection222
- drug ineffective196
- cytomegalovirus infection179
- acute kidney injury178
- product storage error177
- covid-19149
- hospitalisation128
- pyrexia117
- thrombotic microangiopathy105
- diarrhoea101
- urinary tract infection97
- post transplant lymphoproliferative disorder95
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 13 |
| 2009 | 37 |
| 2010 | 30 |
| 2011 | 65 |
| 2012 | 106 |
| 2013 | 231 |
| 2014 | 183 |
| 2015 | 174 |
| 2016 | 246 |
| 2017 | 264 |
| 2018 | 298 |
| 2019 | 265 |
| 2020 | 383 |
| 2021 | 394 |
| 2022 | 372 |
| 2023 | 530 |
| 2024 | 449 |
| 2025 | 460 |
| 2026 | 232 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,420 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| kidney transplant rejectionSignal | 222 | 215.3 | 188.7 | 44,961 |
| transplant rejectionSignal | 231 | 131.7 | 115.9 | 28,983 |
| post transplant lymphoproliferative disorderSignal | 95 | 84.4 | 69.0 | 7,603 |
| thrombotic microangiopathySignal | 105 | 48.3 | 40.0 | 4,770 |
| cytomegalovirus infectionSignal | 179 | 48.3 | 41.8 | 8,164 |
| product storage errorSignal | 177 | 9.0 | 7.8 | 1,252 |
| acute kidney injurySignal | 178 | 5.2 | 4.5 | 598 |
| covid-19Signal | 149 | 3.8 | 3.2 | 303 |
| hospitalisationSignal | 128 | 3.7 | 3.1 | 251 |
| urinary tract infectionSignal | 97 | 2.5 | 2.1 | 88 |
| off label useSignal | 463 | 2.3 | 2.2 | 372 |
| pyrexia | 117 | 1.5 | 1.3 | 19 |
| death | 232 | 1.2 | 1.1 | 8 |
| diarrhoea | 101 | 0.7 | 0.6 | 14 |
| drug ineffective | 196 | 0.7 | 0.6 | 36 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.